CP
ADMA icon

Caligan Partners’s ADMA Biologics ADMA Stock Holding History

Caligan Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51M Hold
300,000
– – 0.12% 27
2026
Q1 		$2.7M Buy
+300,000
New +$4.73M 0.18% 26

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Caligan Partners's ADMA Position: Q2 2026 in Review

Caligan Partners increased its ADMA Biologics (ADMA) stake by 20% in Q2 2026, buying an estimated $8.83M and bringing the position to 5,725,007 shares worth $47.9M. The position accounts for 2.25% of the portfolio, ranked #9.

Caligan Partners first reported a position in ADMA in Q4 2022 and has held it in 9 quarters since. The position peaked at $54.9M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Caligan Partners held 5,725,007 shares of ADMA Biologics worth $47.9M as of Q2 2026.
  • Caligan Partners bought 968,496 ADMA Biologics shares in Q2 2026, an estimated $8.83M.
  • ADMA Biologics made up 2.25% of Caligan Partners's portfolio in Q2 2026, its #9 holding.
  • Caligan Partners first reported a position in ADMA Biologics in Q4 2022 and has held it in 9 quarters since.
  • Caligan Partners's ADMA Biologics position peaked at $54.9M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.